Teva Pharmaceutical Industries (TEVA) Shares Outstanding (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Shares Outstanding across 17 years of filings, most recently posting $1.3 billion for Q1 2026.

• Quarterly Shares Outstanding rose 1.44% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 1.44% YoY) and the FY2025 annual result came in at $1.3 billion, up 4.75% from the prior year.
• Shares Outstanding climbed to $1.3 billion in Q1 2026, from $1.3 billion in the prior quarter.
• Over five years, Shares Outstanding peaked at $1.3 billion in Q1 2026 and troughed at $1.2 billion in Q1 2022.
• A 5-year average of $1.2 billion and a median of $1.2 billion in 2024 frame the typical range for Shares Outstanding.
• Annual changes were most pronounced in 2022 — Shares Outstanding grew 0.58% — and 2026, when it advanced 1.44%.
• Tracing TEVA's Shares Outstanding over 5 years: stood at $1.2 billion in 2022, then grew by 0.82% to $1.2 billion in 2023, then gained by 1.06% to $1.2 billion in 2024, then advanced by 1.37% to $1.3 billion in 2025, then grew by 1.11% to $1.3 billion in 2026.
• Business Quant data shows TEVA's Shares Outstanding at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.